Latest Healthcare It News

Oneview Healthcare PLC reported a 36% increase in revenue for the first half of 2025, driven by strong deployment activity and new US customers, while managing a wider net loss due to FX impacts and restructuring costs.

Arena REIT reports robust FY2025 financial results marked by earnings growth, a strengthened portfolio, and significant progress on sustainability targets, while guiding higher distributions for FY2026.

Arena REIT reported a robust 17% increase in net operating profit for FY2025, underpinned by strong portfolio management and development activity, while raising its distribution guidance by 5.5% for FY2026.

Arena REIT reported a robust FY25 with net profit up 42% to $81.5 million, driven by rental growth and property revaluations, while raising FY26 distribution guidance by 5.5%. The Group also announced a CEO succession plan amid sustained portfolio expansion and strong capital management.

Recce Pharmaceuticals’ RECCE 327 Topical Gel shows statistically significant superiority over standard antibiotics in treating antibiotic-resistant burn wounds in preclinical models, advancing its U.S. Department of Defense collaboration.

WAM Capital Limited’s July 2025 update reveals a robust net tangible asset position and a healthy interim dividend, underpinned by strong performances from key holdings ALS and HUB24.

Imagion Biosystems has completed the first tranche of its $3.5 million capital raising, issuing 45 million new shares to strengthen its financial position ahead of a key shareholder vote.

Charter Hall Social Infrastructure REIT (CQE) reported solid FY25 results, highlighted by strategic acquisitions, a successful $900 million debt refinancing, and a 10.5% lift in distribution guidance for FY26.

Global Health Limited has secured a $186,748 contract to implement its MasterCare+ digital platform at Jarrah House, enhancing alcohol and other drug (AOD) services with tailored technology solutions.

ResMed Inc. reported a robust 10% increase in revenue to $5.15 billion for fiscal 2025, driven by strong demand in sleep and breathing health devices and residential care software. The company also expanded its diagnostic capabilities with the acquisition of VirtuOx, positioning itself for further growth in home-based health solutions.

AVITA Medical reported a 21% revenue increase in Q2 2025 driven by expanded sales and new product launches, yet continues to face net losses and liquidity challenges requiring loan covenant waivers.

AVITA Medical’s Q2 2025 update reveals a temporary setback in RECELL demand due to Medicare reimbursement delays, offset by strong revenue growth and promising clinical data. The company anticipates recovery and renewed growth in the second half of the year.